|
|
 |
|
Viewing report
|
|
|
|
Product Profiles: Alzheimer's Disease - Immunotherapies can revolutionize treatment paradigm
Datamonitor, Nov 2011, Pages: 150
The beta-amyloid hypothesis has so far failed to deliver a viable candidate, contributing to an absence of new market entrants over the past decade. However, given the weight of candidates with disease-modifying potential in the pipeline, new drugs are expected to emerge that will satisfy one of the biggest unmet needs in the industry – a treatment that slows Alzheimer’s disease neurodegeneration.
Features and benefits
- Understand Datamonitor’s independent appraisal of marketed brands and key pipeline agents indicated for treating Alzheimer’s disease.
- Illustrate how pipeline and marketed drugs compare to one another in terms of clinical and commercial attributes.
- Review important clinical developments for key pipeline agents with analysis of the latest clinical trial data.
- Understand how marketed brands are positioned in the Alzheimer’s disease treatment algorithm.
- Determine to what extent future therapies satisfy the main clinical unmet needs in Alzheimer’s disease treatment.
Highlights
- Datamonitor’s physician survey reveals that Aricept finds widespread use across all lines of therapy and severities, from mild cognitive impairment to severe Alzheimer’s disease. However, Eisai faces a steep decline in revenues as generic donepezil take hold in the US, marketed competition heightens in Japan, and European patents near expiry.
- Bapineuzumab and solanezumab have the potential to revolutionize Alzheimer’s disease treatment and become future market leaders. However, each program carries a caveat. J&J/Pfizer are relying on post-hoc analyses of bapineuzumab in a subpopulation while Lilly is betting on solanezumab’s Phase II biomarker effect translating into tangible benefits.
- A precedent already exists for neurotransmitter mechanisms, ensuring a higher likelihood of navigating through clinical trials. Late-stage symptomatic drugs include Eisai’s Aricept patch and GSK’s 5-HT6 receptor agonist SB-742457, although the potential rewards on offer for these candidates are lower than for the immunotherapies.
Your key questions answered
- How do drugs in development compare to the current gold-standard treatment for Alzheimer’s disease?
- Which are the most likely drugs to emerge from the pipeline and how will they impact the way Alzheimer’s disease is treated?
- How are marketed brands positioned in the Alzheimer’s disease treatment algorithm?
- What are the comparative strengths and weaknesses of the key Alzheimer’s disease brands and pipeline candidates?
|
|
|
|
